ES2575995T3 - Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal - Google Patents
Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal Download PDFInfo
- Publication number
- ES2575995T3 ES2575995T3 ES11815379.0T ES11815379T ES2575995T3 ES 2575995 T3 ES2575995 T3 ES 2575995T3 ES 11815379 T ES11815379 T ES 11815379T ES 2575995 T3 ES2575995 T3 ES 2575995T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- hydroxyethoxy
- carboxamide
- fluoro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012824 ERK inhibitor Substances 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title abstract 2
- 208000012239 Developmental disease Diseases 0.000 title 1
- 230000005856 abnormality Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 abstract 1
- JLOXTZFYJNCPIS-FYWRMAATSA-N (z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(\C#N)=C(/N)SC1=CC=C(N)C=C1 JLOXTZFYJNCPIS-FYWRMAATSA-N 0.000 abstract 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical group COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 abstract 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 abstract 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 abstract 1
- QGJGAJFLNBOEHE-UHFFFAOYSA-N 2-(4-chloro-2-fluoroanilino)-n-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(Cl)C=C1F QGJGAJFLNBOEHE-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-amino-2H-pyrazolo [3,4-c] pyridazin-5-yl Chemical group 0.000 abstract 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 abstract 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 abstract 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 abstract 1
- 210000001766 X chromosome Anatomy 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 abstract 1
- 229940005608 hypericin Drugs 0.000 abstract 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 5
- 206010038669 Respiratory arrest Diseases 0.000 description 3
- 238000013105 post hoc analysis Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos inhibidores de ERK en solitario o en combinación que evitan anomalías en la conectividad neuronal; o una sal farmacéuticamente aceptable y/o uno o más estereoisómeros de los mismos; para su uso en el tratamiento de síndrome del cromosoma X frágil o trastornos del espectro autista asociados a anomalías de ERK, en los que el inhibidor de ERK se selecciona entre el grupo que consiste en 2-(2-amino-3- metoxifenil)-4H-cromen-4-ona, (2Z,3Z)-bis{amino[(2-aminofenil)sulfanil]metilideno}butanodinitrilo, 5-[(4-bromo-2- clorofenil)amino]-4-fluoro-N-(2-hidroxietoxi)-1-metil-1H-bencimidazol-6-carboxamida, 2-[(2-fluoro-4-yodofenil)amino]- N-(2-hidroxietoxi)-1,5-dimetil-6-oxo-1,6-dihidropiridin-3-carboxamida, 2-(4-cloro-2-fluoro-anilino)-N-(2-hidroxietoxi)- 1,5-dimetil-6-oxo-piridin-3-carboxamida, 2-[(2-cloro-4-yodofenil)amino]-N-(ciclopropilmetoxi)-3,4-difluorobenzamida, (3R,4R)-4-(3,4-Dimetoxibencil)-3-(4-hidroxi-3-metoxibencil)dihidrofuran-2(3H)-ona, (2Z)-3-amino-3-[(4- aminofenil)sulfanil]-2-[2-(trifluorometil)fenil]prop-2-enenitrilo, hipericina, 3-(3-amino-2H-pirazolo[3,4-c]piridazin-5-il)-2- fenil-3H-pirazolo[ 1,5-a]piridin-8-io, y ácido 2-cloro-4-{[2-{[(2R)-1-hidroxi-3-metilbutan-2-il]amino}-9-(propan-2-il)-9Hpurin- 6-il]amino}benzoico.
Description
Análisis estadístico
Los datos se analizaron por análisis de varianza (ANOVA) seguido de comparaciones post-hoc con pruebas de Fisher cuando fue apropiado. Un efecto se consideró significativo si p < 0,05. Los datos se presentan como la media error estándar de la media.
RESULTADOS
Latencia de convulsiones
Los efectos de MPEP y alcohol perílico sobre la latencia de aparición de convulsiones se muestran en la figura 6. El análisis ANOVA descubrió un efecto del tratamiento significativo. Un análisis post hoc mostró que MPEP y alcohol perílico (25 y 50 mg/kg) aumentaron la latencia de convulsiones en comparación con el vehículo respectivo.
Latencia del paro respiratorio
Los efectos de MPEP y alcohol perílico sobre la latencia del paro respiratorio (y posterior muerte) se muestran en la figura 7. El análisis ANOVA descubrió un efecto del tratamiento significativo. El análisis post hoc descubrió que MPEP y alcohol perílico (25 y 50 mg/kg) prolongaron significativamente la latencia del paro respiratorio en comparación con el vehículo respectivo. Los ratones tratados con MPEP (30 mg/kg) no mostraron dificultad respiratoria durante los ensayos y, por lo tanto, a todos se les dio una latencia de 240 s.
Escala de convulsiones media
Los efectos de MPEP y alcohol perílico sobre la escala de convulsiones media se muestran en la figura 8. El análisis ANOVA descubrió un efecto del tratamiento significativo. Un análisis post hoc mostró que, en comparación con el vehículo, MPEP y alcohol perílico (25 y 50 mg/kg) redujeron significativamente la escala de convulsiones.
16
Claims (1)
-
imagen1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37085410P | 2010-08-05 | 2010-08-05 | |
| US370854P | 2010-08-05 | ||
| US40536910P | 2010-10-21 | 2010-10-21 | |
| US405369P | 2010-10-21 | ||
| PCT/US2011/046773 WO2012019113A2 (en) | 2010-08-05 | 2011-08-05 | Inhibitors of erk for developmental disorders of neuronal connectivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2575995T3 true ES2575995T3 (es) | 2016-07-04 |
Family
ID=45560094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11815379.0T Active ES2575995T3 (es) | 2010-08-05 | 2011-08-05 | Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150141380A1 (es) |
| EP (1) | EP2600862B1 (es) |
| KR (1) | KR20130113430A (es) |
| CN (1) | CN103221043B (es) |
| AU (1) | AU2011285611B2 (es) |
| CA (1) | CA2807510A1 (es) |
| ES (1) | ES2575995T3 (es) |
| WO (1) | WO2012019113A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835513B2 (en) * | 2013-06-28 | 2020-11-17 | The Regents Of The University Of California | Methods and treatments for the learning and memory deficits associated with Noonan syndrome |
| CN108024990B (zh) * | 2015-08-31 | 2020-08-11 | 深圳青雅启瑞生物科技有限公司 | 美金刚与牛蒡子苷元的缀合物及其组合物和用途 |
| ES2883639T3 (es) | 2017-10-17 | 2021-12-09 | Atriva Therapeutics Gmbh | Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas |
| EP3765087A1 (en) * | 2018-04-13 | 2021-01-20 | Healx Limited | Kit, composition and combination therapy for fragile x syndrome |
| IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| WO2023196412A1 (en) * | 2022-04-06 | 2023-10-12 | Nobias Therapeutics, Inc. | Liquid formulations comprising mitogen-activated protein kinase kinase (mek) inhibitors and methods using same |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US6821963B2 (en) | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6573044B1 (en) | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6319955B1 (en) | 1998-01-06 | 2001-11-20 | The General Hospital Corporation | Use of MEK1 inhibitors as protective agents against damage due to ischemia |
| AU1951499A (en) | 1998-01-06 | 1999-07-26 | General Hospital Corporation, The | Use of mek1 inhibitors as protective agents against damage due to ischemia |
| IT1299195B1 (it) | 1998-06-25 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati |
| US6147107A (en) | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| US6063383A (en) | 1999-01-28 | 2000-05-16 | Hsu; Wu-Ching | Pharmaceutical suppository composites for fever and influenza and method of producing the composites |
| US6703420B1 (en) * | 1999-03-19 | 2004-03-09 | Bristol-Myers Squibb Pharma Company | Amino-thio-acrylonitriles as MEK inhibitors |
| AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| CA2369076A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| US20020058699A1 (en) * | 2000-06-30 | 2002-05-16 | Sweatt J. David | Methods for treating seizure disorders by inhibiting MAPK pathway activation |
| DE60122176T2 (de) | 2000-09-15 | 2007-07-05 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazole und ihre verwendung als erk-inhibitoren |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US6949558B2 (en) | 2001-11-07 | 2005-09-27 | Yale University | Enhancement of taxane-based chemotherapy by a CDK1 antagonist |
| WO2003066556A1 (en) | 2002-02-05 | 2003-08-14 | Hormos Medical Corporation | Lignan derivatives |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2005028426A1 (ja) * | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| MY144232A (en) * | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| WO2006134469A1 (en) * | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| EP2710893A1 (en) * | 2009-08-03 | 2014-03-26 | Theta Biomedical Consulting&development Co., Inc | Methods of treating autism spectrum disorders and compositions for same |
-
2011
- 2011-08-05 US US13/814,393 patent/US20150141380A1/en not_active Abandoned
- 2011-08-05 ES ES11815379.0T patent/ES2575995T3/es active Active
- 2011-08-05 CN CN201180043887.7A patent/CN103221043B/zh not_active Expired - Fee Related
- 2011-08-05 CA CA2807510A patent/CA2807510A1/en not_active Abandoned
- 2011-08-05 AU AU2011285611A patent/AU2011285611B2/en not_active Ceased
- 2011-08-05 EP EP11815379.0A patent/EP2600862B1/en not_active Not-in-force
- 2011-08-05 WO PCT/US2011/046773 patent/WO2012019113A2/en not_active Ceased
- 2011-08-05 KR KR1020137005737A patent/KR20130113430A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20150141380A1 (en) | 2015-05-21 |
| CN103221043A (zh) | 2013-07-24 |
| CA2807510A1 (en) | 2012-02-09 |
| CN103221043B (zh) | 2016-04-06 |
| EP2600862A2 (en) | 2013-06-12 |
| KR20130113430A (ko) | 2013-10-15 |
| AU2011285611B2 (en) | 2014-10-02 |
| AU2011285611A1 (en) | 2013-03-14 |
| EP2600862B1 (en) | 2016-04-20 |
| WO2012019113A3 (en) | 2012-08-09 |
| WO2012019113A2 (en) | 2012-02-09 |
| EP2600862A4 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2575995T3 (es) | Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| PE20142316A1 (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES | |
| AR059087A1 (es) | Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas. | |
| US9975852B2 (en) | Quinoline sulfonyl derivatives and uses thereof | |
| CL2008003326A1 (es) | Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras. | |
| ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| JP2008516986A5 (es) | ||
| ES2634562T3 (es) | Métodos y composiciones para tratar hiperuricemia y trastornos metabólicos asociados con hiperuricemia | |
| CO6150162A2 (es) | Pirrolopirimidinas para composiciones farmaceuticas | |
| EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| CO6150139A2 (es) | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su | |
| JP2010531345A5 (es) | ||
| AR053569A1 (es) | Derivados de pirazol | |
| PE20130221A1 (es) | Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
| RU2007145935A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
| NZ579296A (en) | Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections | |
| JP2010518056A (ja) | β−２−アドレナリン受容体作動性ベンゾチアゾロンの組み合わせ剤 | |
| ES2670686T3 (es) | Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico |